With the notable exceptions of Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY), biotechnology stocks had a rough time attracting investment capital in 2024. Small- and mid-cap biotech ...

Artificial intelligence (AI) has the potential to transform several different areas of the healthcare industry.

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

GLP-1 drugs, which have seen widespread success, have been linked to a number of cases of pancreatitis in the UK, which have ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Amy Spencer, a Missouri-based pioneer, navigates the unregulated gray market of obesity medicines. Utilizing drugs like Eli Lilly's Zepbound under the radar, Spencer reduces her weight and costs ...

If you’ve been waiting for the chance for weight loss injections to drop in price, there are more options turning up to ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...

The U.K. is asking patients whose pancreas became dangerously inflamed after taking obesity drugs like Wegovy and Zepbound to ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...